Sanofi unveils positive Lemtrada data as it awaits FDA approval; Aspen looking to continue its deal streak;

@FiercePharma: Immunotherapy vaccine combo cuts recurrence in HER2 breast cancer patients. News | Follow @FiercePharma

@EricPFierce: Merck & Co is again shipping BCG vaccine but Sanofi is not. Story | Follow @EricPFierce

@CarlyHFierce: FDA approves Sanofi's Menactra as meningococcal booster. More | Follow @CarlyHFierce

> GlaxoSmithKline ($GSK) is trying again to move some Paxil birth defect lawsuits to federal court from a state court in Delaware. Report

> As it awaits FDA approval for MS med Lemtrada, Sanofi ($SNY) has unveiled data on the drug that show lasting benefits. Release

> Riding high on deals with Glaxo ($GSK) and Merck ($MRK), South Africa's Aspen is now seeking further acquisitions. Report

> The FDA is inspecting the Gujarat, India, plant of Sun Pharma's U.S. subsidiary, Caraco Pharmaceutical Laboratories. More

> Opioid abuse-fighters are aiming to combat the problem with continuing medical education. More

Medical Device News

@FierceMedDev: Med tech M&A beware: Top Senate Democrats reveal plan to crack down on inversions. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: ACLA head makes case against FDA LDT regulation to Congress. Story | Follow @VarunSaxena2

@MichaelGFierce: ICYMI: UO, Berkeley team tailors ultrathin peptoid nanosheets for delivery using oil and water. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Top Senate Democrats unveil plans to curb corporate tax inversions. Reuters story | Follow @EmilyWFierce

> Harvard gets DARPA grant to develop soft, mobility exosuit. More

> Blackberry to integrate medical devices in India. Article

> Med tech M&A beware: Top Senate Democrats reveal plan to crack down on inversions. Story

Biotech News

@FierceBiotech: Gates Foundation adds $50M to help speed Ebola drug development efforts. Story | Follow @FierceBiotech

@JohnCFierce: Analysts: Pfizer execs say they're locked-and-loaded on tax inversion, and open to targets - via @TracyStaton. Article | Follow @JohnCFierce

@DamianFierce: Biotech's sprawling PED scandal widens as @adamfeuerstein admits that he "juices" daily. Report | Follow @DamianFierce

@EmilyMFierce: Uh oh. Survival rate of Ebola may be less than what we think. More from Science | Follow @EmilyMFierce

> Baxalta: Baxter's newly named biopharma spinout has had its ups and downs. Article

> Virobay tees up a $50M IPO to get a trio of candidates into Phase II. More

> Sanofi keeps the faith in MS and eyes a new dawn for Genzyme. News

Vaccines News

> Glaxo's Ebola vaccine passes key animal test as human trials begin. News

> Immunotherapy vaccine combo cuts recurrence in HER2 breast cancer patients. More

> New problems at GSK flu vaccine plant will impact U.S., Canada orders. Story

> Takeda on track for dengue vaccine nods in 2017-18. Article

> FDA approves Sanofi's Menactra as meningococcal booster. Item

Pharma Manufacturing News

> Apotex recalls Paxil tainted at GSK plant. Story

> Sources: FDA inspectors in Sun plant that has had recalls. More

> FDA fight with compounder tests its patience and its limits. Article

> Hospira will prep Indian workers at Vizag 'university.' Story

> Merck again shipping BCG cancer treatment but Sanofi still is not. Report

And Finally... In a randomized trial, Insulin degludec given once daily proved noninferior to insulin detemir in children and adolescents with Type 1 diabetes. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.